Date: Nov 24, 2015 Author: Damian Garde Source: Fierce Biotech (
click here to go to the source)
Presage Biosciences, a popular partner for oncology drug developers, is wading into clinical development of its own, in-licensing a candidate and using its technology to spotlight potential combination therapies. The Seattle biotech acquired the rights to voruciclib, an oral CDK inhibitor, from India's Piramal Enterprises. Presage now plans to use its proprietary CIVO technology, which allows for the testing of cancer combinations on living tumors, to identify a path forward with the drug. To date, the company's development platform has helped it land agreements with Takeda and Celgene ($CELG).